SBIR/STTR Research Award
RAPID POINT OF CARE DETECTION TESTS FOR SEROLOGIC STATUS OF INDIVIDUALS FOR CMV AND HSV INFECTIONS
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- QOOLABS INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- K7HZKKAMVHK5
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
To develop lateral flow immunoassays LFIA for CMV and HSV antibody detection that will be rapid accurate cost effective and suitable for use at point of care
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GUINEA PIGS IL1B, IL2, IL4, IL6, IL8, IL10, IL12, AND IL13.
- SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
- Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)
- SBIR TOPIC 107 AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GOLDEN HAMSTER
- Rapid at-home Detection for Serologic Status of Hepatitis C Virus (HCV) Infection
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
16 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $7,488,575. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services